Lynn M. Barker, MT (ASCP)

Ms. Barker is a proven leader in the clinical and research laboratory.  With over 25 years of diverse experience in healthcare, biotechnology and pharmaceutical industries and more than 20 publications as author/co-author, Lynn is an asset to both R&D and strategic business planning.  Utilizing her extensive knowledge of clinical microbiological procedures and experience in clinical blood banking, she organizes and directs the daily activities of the microbiology laboratory including quality control procedures.  She executes specialized laboratory techniques with impeccable documentation and work standards. She is an enthusiastic team member dedicated to day-to-day productivity and thriving on organization, staff training and long-term planning.

Steven Geelhood

Mr. Geelhood has a Masters of Science in Chemical Engineering from the University of Washington where he worked with biomaterials and the interactions of proteins and cells on surfaces.  He has over 5 years of experience in the medical device industry, leading the engineering development of the pH1000 system.  He brings a balanced background of chemistry know how, process improvement and project management to the team.

Daniel Gestwick

Mr. Gestwick is a mechanical engineer with a Master of Engineering Management from the Thayer School of Engineering at Dartmouth College. His professional experience has spanned multiple industries with companies such as GE, Z Corporation and K2. He brings a background in both product design and manufacturing management to help BCSI bring our Nucleic Acid System to market.

Perry Hargrave

Mr. Hargrave is a University of Washington Bioengineering graduate, and is responsible for the development and management of instrumentation associated with BCSI technologies. Prior to BCSI Perry worked as a research associate at the University of Washington Cogent Systems Lab analyzing tetranucleotide structure and developed temperature control system for microfluidic studies.

Paul Haydock, Ph.D.

Dr. Haydock is responsible for technical development of nucleic acid extraction technology. He received his PhD from Purdue University and did his postdoctoral work at the University of Washington. He has extensive experience in new technology development, product development, and nucleic acid amplification technologies. Dr. Haydock worked on the development of diagnostic assays for a variety of human pathogens. He contributed to an FDA application for a diagnostic assay for dental pathogens that could be used in a dental office. Another product for which he was responsible that detects certain toxic algal species was adopted by New Zealand as a standard assay method. He has worked not only in research and development, but in manufacturing, QC, and documentation. He helped found Saigene Corporation in Seattle, worked in the laboratory, managed research staff, and gave numerous business presentations. In addition, he handled new customer development and customer relations. He has obtained several small business grants and is co-author on 7 issued U.S. patents and several applications, and is co-author on 20 publications. He is a regular grant reviewer for an army research program and has taught chemistry at a local college.

Harvey Hoyt, MD

Dr. Hoyt is responsible for business and financial planning, fund raising, and business and commercial development at BCSI. He has extensive knowledge of the blood storage industry, based on thirteen years at Baxter International, followed by nine years at a number of other medical diagnostics and supply companies. Dr. Hoyt has had a wide variety of experience in the pharmaceutical industry (therapeutics, in vitro diagnostics, and biologics) in R&D, technical development, business development, and general management at the COO and CEO levels, both in major corporations and start-up companies. He has had P&L responsibilities, formulated strategic and operational business plans, developed organizations, partnered with industries and universities, licensed products in and out, and raised investments for start-ups having been involved in over $150 million of private and public equity funding. Dr. Hoyt has played key roles in gaining FDA approval of eighty 510(k) and nineteen new drug Applications and product marketing applications. These products had annual sales exceeding $7 billion.

Evert Jan Klip

Mr. Klip has overall responsibility for European operations. He was educated as a bio-mechanical engineer and has over 28 years of international experience in developing, registering, manufacturing and commercializing medical devices and pharmaceuticals. His management positions have included Pfizer, Baxter International, AKZO Pharma, and NPBI International. At NPBI he had overall responsibility as VP-R&D for research and development of a broad range of products for the blood transfusion market. He has been member of the ISBT and industrial member of the BEST group. Evert Jan is recognized by the international blood banking community. He has served as a consultant to industry, universities and government agencies.

Oliver Z Nanassy, Ph.D.

Dr. Nanassy has over 19 years of clinical and biomedical research experience and joined BCSI to lend his expertise to develop analytical technology for use in pathogen detection. His previous work with nucleic acid extraction and biochemistry, bacterial detection, and fluorescence sensors adds significant value to the Company’s core technologies. His responsibilities include managing inter-departmental and external research efforts as well as supporting marketing efforts in the field and through interactions with potential partners. As a Ruth L. Kirchstein Fellow at Harvard University he developed novel cell-based assays and computational approaches towards implementation of a $400,000 live-cell imaging facility. The effort was critical to analyze mechanisms important for proper disjunction of chromosomes that underlie the pathology of Down’s syndrome and Ataxia Talengictasia, two debilitating human diseases. Dr. Nanassy’s research portfolio includes several publications and $400,000 in previous funding awards from the National Institutes of Health and the National Science Foundation. Dr. Nanassy is a member of the American Association for Advancement of Science and the American Society of Microbiology.

Michael Reed, Ph.D.

Dr. Reed is responsible for R&D at the company. He is a PhD chemist with 17 years of experience in the development of biotech products. His expertise is in linking biological active molecules (antibodies, DNA probes, therapeutics) to other signal molecules or surfaces. He led development of many different types of these "bioconjugates" for use in medical devices and in diagnostic products. He has a strong background in R&D management, technology presentation (over 50 published papers), and intellectual property (twelve issued U.S. patents).

Dennis Streppa

Mr. Streppa has over 30 years experience in global healthcare sales, marketing and general management. Prior to joining BCSI, he served as Senior Vice President/General Manager of Cardinal Health's Fluid Management and Gloves business. He has also been with Pfizer Inc, American Hospital Supply, Baxter Healthcare and Allegiance Healthcare. He is a graduate of the University of Maryland and Northwestern University, Kellogg School of Business Executive Masters Program. Dennis is an avid triathelete, terrible golfer and is looking forward to the Cubs beating the Mariners in the World Series. He and his wife Denise have three daughters and two sons and reside in Lake Bluff, Illinois.